Other Controls and Reagents
Avanti Polar Lipids 17:0 Lyso PI-d5, 500µg
1-heptadecanoyl-2-hydroxy-sn-glycero(d5)-3-phosphoinositol (ammonium salt)
Avanti Polar Lipids 330820 ULTIMATESPLASH ONE
330820 UltimateSPLASH ONEUltimateSPLASH ONE Internal Standard for Lipidomic Analysis
eMolecules 1224606-06-7 | D-Lin-MC3-DMA | Target Molecule642.110 | C43H79NO2 | 0.000 | CCCCC\C=C/C\C=C/CCCCCCCCC(CCCCCCCC\C=C/C\C=C/CCCCC)OC(=O)CCCN(C)C | 5mg | 495883820
D-Lin-MC3-DMA | Target Molecule | 1224606-06-7642.110 | C43H79NO2 | 0.000 | CCCCC\C=C/C\C=C/CCCCCCCCC(CCCCCCCC\C=C/C\C=C/CCCCC)OC(=O)CCCN(C)C | 5mg | 495883820
![Medchemexpress LLC 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium | 247925-28-6 | 98.0% | 2808.74 | 50 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000435895-Logo.png-250.jpg){kind=logo}
Medchemexpress LLC 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium | 247925-28-6 | 98.0% | 2808.74 | 50 MG
18:0 mPEG2000 PE sodium is a phospholipid-polyethylene glycol conjugate, serving as a key PEG lipid component in lipid nanoparticles (LNPs). It is utilized in gene transfection, drug carrier systems, and drug delivery research. This compound possesses both hydrophilic and hydrophobic properties, enabling it to encapsulate drugs within liposomes, thereby enhancing their stability and efficacy.
- Conjugate of phospholipid and polyethylene glycol.
- Serves as a key PEG lipid component in lipid nanoparticles (LNPs).
- Applicable in gene transfection research.
- Useful in drug carrier development.
- Supports drug delivery applications.
- Exhibits both hydrophilic and hydrophobic characteristics.
- Capable of encapsulating drugs within liposomes.
- Enhances drug stability and efficacy.
eMolecules BP Lipid 800 | Broadpharm |858.340 | C50H99NO9 | 85.000 | CCCCCCCCC(CCCCCCCC)OC(=O)CCOCCOCCN(CCO)CCOCCOCCC(=O)OC(CCCCCCCC)CCCCCCCC | 10mg | 718091575
BP Lipid 800 | Broadpharm |858.340 | C50H99NO9 | 85.000 | CCCCCCCCC(CCCCCCCC)OC(=O)CCOCCOCCN(CCO)CCOCCOCCC(=O)OC(CCCCCCCC)CCCCCCCC | 10mg | 718091575
Avanti Polar Lipids 26,26,26,27,27,27-hexadeuteriolanosta-8,24-dien-3ß-ol, 28290-39-3, 1 mg
Molecular Formula: C30H44D6O, Formula Weight: 432.754, Purity >99%.
![Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000385579-logo.png-250.jpg){kind=logo}
Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 25 MG
DSPE-PEG (2000)-COOH is a pegylated derivative of 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine. This compound is capable of forming micelles for targeted drug delivery.
- Can form micelles for targeted drug delivery
- Useful for polyvalent targeted delivery of vinorelbine to cancer cells
- Can be used as optical coherence tomography contrast agents for tumor angiography in live animals
- Targets liposome
- Pathway: Metabolic enzyme/protease
- Powder stable at -20°C for 3 years
- In solvent stable at -80°C for 6 months, and at -20°C for 1 month
- Solubility in H2O: 25 mg/mL (requires ultrasonic treatment)
- Solubility in DMSO: 25 mg/mL (requires ultrasonic, warming, and heating to 60°C)
- Achieves a clear solution at ≥ 2.5 mg/mL in specific in vivo solvent combinations
- For research use only
Avanti Polar Lipids 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine | 26853-31-6 | 760.1 g/mol | 25MG
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine | 26853-31-6 | 760.1 g/mol | 25MG
Avanti Polar Lipids 1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt), 104872-42-6, MFCD00145456, 200mg
Molecular Formula: C42H84ClNO2, Formula Weight: 670.575, Purity >99%.
(=O)OCCNC(=O)CCCCCN)OC(=O)CCCCCCCCCCCCCCC | 25mg | 718091965](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502474708.JPG-250.jpg)
eMolecules 115288-21-6 | 16:0 Caproylamine PE | Broadpharm805.132 | C43H85N2O9P | 0.000 | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)CCCCCN)OC(=O)CCCCCCCCCCCCCCC | 25mg | 718091965
16:0 Caproylamine PE | Broadpharm | 115288-21-6805.132 | C43H85N2O9P | 0.000 | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)CCCCCN)OC(=O)CCCCCCCCCCCCCCC | 25mg | 718091965